Franz v. Purdue Pharma Co.

2006 DNH 024
CourtDistrict Court, D. New Hampshire
DecidedFebruary 22, 2006
DocketCV-05-201-PB
StatusPublished

This text of 2006 DNH 024 (Franz v. Purdue Pharma Co.) is published on Counsel Stack Legal Research, covering District Court, D. New Hampshire primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Franz v. Purdue Pharma Co., 2006 DNH 024 (D.N.H. 2006).

Opinion

Franz v . Purdue Pharma Co. CV-05-201-PB 2/22/06

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE

Charlene E . Franz

v. Case N o . 05-cv-201-PB Opinion N o . 2006 DNH 024 Purdue Pharma Co. et a l .

MEMORANDUM AND ORDER

This action stems from plaintiff Charlene E . Franz’s use of

OxyContin, a prescription painkiller she took at the direction of

her doctors. Franz alleges that she became addicted to the drug

and suffered bodily and mental harm as a result. She asserts a

variety of claims against defendants The Purdue Pharma Company,

Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick

Company, and The P.F. Laboratories (collectively, “Purdue”), as

well as against defendants The Abbott Laboratories and Abbott

Laboratories, Inc. (collectively, “Abbott”) and defendant

Mallinckrodt, Inc. (“Mallinckrodt”). Purdue has filed a motion

for summary judgment (Doc. N o . 13) in which Abbott and Mallinckrodt have joined.1 For the following reasons, I grant

defendants’ motion.

I. FACTUAL BACKGROUND2

Purdue manufactures, markets, and distributes OxyContin, a

prescription opioid analgesic drug that is sold in tablet form.

Compl. ¶¶ 3 0 , 3 2 . Abbott also markets and distributes OxyContin.

Id. ¶ 3 3 . Purdue designed OxyContin, id. ¶ 3 2 , which contains

oxycodone hydrochloride. Id. ¶ 3 4 . Mallinckrodt supplies

oxycodone hydrochloride to Purdue. Id.

In 1996, Franz’s doctors prescribed OxyContin to help her

manage a painful condition. Pl.’s B r . at 1 ; Med. Rec. 10/11/96.

Franz became addicted to the drug, Pl.’s B r . at 1 , which is a

Schedule II controlled substance under federal law. Compl. ¶ 1 .

In October 2000, Franz was hospitalized for addiction to and

withdrawal from OxyContin. Pl.’s B r . at 1 . In April 2004, she

1 Purdue’s arguments apply to Franz’s claims against Mallinckrodt and Abbott, including those that name only Mallinckrodt as a defendant. Accordingly, I treat the defendants as a group. 2 I describe the facts in the light most favorable to Franz, the non-moving party.

-2- filed this lawsuit.3 She alleges that OxyContin and oxycodone

hydrochloride are defective and unreasonably dangerous, that

OxyContin was marketed based on fraudulent misrepresentations

about its efficacy and sold without adequate instructions and

warnings, and that Purdue and Abbott conspired to increase

OxyContin’s market share. Her complaint includes claims for

strict products liability, negligence, breach of the implied

warranty of merchantability, fraud, and civil conspiracy.

II. STANDARD OF REVIEW

Summary judgment is appropriate “if the pleadings,

depositions, answers to interrogatories, and admissions on file,

together with the affidavits, if any, show that there is no

genuine issue as to any material fact and that the moving party

is entitled to a judgment as a matter of law.” Fed. R. Civ. P.

56(c). In ruling on a motion for summary judgment, I construe

the evidence in the light most favorable to the nonmovant.

Navarro v . Pfizer Corp., 261 F.3d 9 0 , 94 (1st Cir. 2001).

3 Franz originally filed this action in the Southern District of Illinois. Purdue moved to have it transferred to South Carolina and then to New Hampshire. Def.’s B r . at 2 .

-3- The party moving for summary judgment “bears the initial

responsibility of . . . identifying those portions of [the

record] which it believes demonstrate the absence of a genuine

issue of material fact.” Celotex Corp. v . Catrett, 477 U.S. 3 1 7 ,

323 (1986). Once the moving party has met its burden, the burden

shifts to the adverse party to “produce evidence on which a

reasonable finder of fact, under the appropriate proof burden,

could base a verdict for i t ; if that party cannot produce such

evidence, the motion must be granted.” Ayala-Gerena v . Bristol

Myers-Squibb Co., 95 F.3d 8 6 , 94 (1st Cir. 1996).

III. ANALYSIS

A. Strict Products Liability, Negligence, Fraud, and Conspiracy

Defendants argue that Franz’s claims for strict products

liability, negligence, fraud, and conspiracy are time-barred.

The parties agree that this procedural issue is governed by

Illinois law. See Def.’s B r . at 7 ; Pl.’s B r . at 3 n.3. Illinois

has a two-year statute of limitations for “actions for damages

for injury to the person.” § 735 Ill. Comp. Stat. § 5/13-202.

Franz’s strict products liability, negligence, fraud, and

-4- conspiracy claims are subject to the statute of limitations.4

Franz filed this action in April 2004, so her personal

injury claims are time-barred if the statute of limitations began

to run before April 2002. Defendants argue that the statute

began to run in October 2000, when Franz was hospitalized for

addiction to and withdrawal from OxyContin. In response, Franz

invokes the Illinois “discovery rule” and contends that the

limitations period did not commence until she realized that

defendants wrongfully caused her injuries. She claims that she

“blamed herself for her addiction” until April 2003, in part

because her doctor told her that OxyContin was safe and non-

addictive when he prescribed it for her. Pl.’s B r . at 5 ; Franz

Aff. ¶ 4 . In April 2003, Franz allegedly heard about a

4 Franz has not objected to defendants’ categorization of her fraud and conspiracy claims as personal injury actions. In Illinois, “[t]he determination of the applicable statute of limitations is governed by the type of injury at issue, irrespective of the pleader’s designation of the nature of the action.” Armstrong v . Guigler, 174 Ill. 2d 2 8 1 , 286 (Ill. 1996). Here, Franz has asserted claims for fraud and conspiracy, but the injuries she allegedly suffered as a result of defendants’ conduct are clearly personal in nature. Accord Pavlik v . Kornhaber, 326 Ill. App. 3d 7 3 1 , 748 (Ill. App. 2001) (“Although count III is styled as a fraud claim, plaintiff alleges the same personal injuries alleged in her negligence count . . . . plaintiff’s fraud count is controlled by the statute of limitations for personal injuries.”).

-5- television advertisement “concerning problems with OxyContin,”

Franz Aff. ¶ 8 , and realized that defendants might have been

responsible for her injuries. Id. ¶ 9.

The Illinois discovery rule provides that “[a]n injured

party’s cause of action accrues, and the statute of limitations

begins to run, when that person knows or reasonably should have

known of the injury and also knows or reasonably should have

known that the injury was caused by the actions of another.”

Kumpfer v . Shiley, Inc., 741 F. Supp. 7 3 8 , 739 (N.D. Ill. 1990).

“When the plaintiff becomes apprised of this knowledge, she is

under an obligation to further determine whether an actionable

wrong has been committed.” Id. Illinois law does not require

that a person have actual knowledge of another’s wrongful conduct

before the limitations period begins to run. Curry v . A.H.

Robins Co., 775 F.2d 2 1 2 , 216 (7th Cir. 1985). Instead, a court

must determine when “a reasonable person would have realized

[that her injuries] might have been the result of actionable

conduct.” Id. Although this is often a question of fact, where

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Victor Essil Quinn
95 F.3d 8 (Eighth Circuit, 1996)
Hockman v. United States
741 F. Supp. 5 (District of Columbia, 1990)
Witherell v. Weimer
421 N.E.2d 869 (Illinois Supreme Court, 1981)
Town of Hooksett School District v. W.R. Grace & Co.
617 F. Supp. 126 (D. New Hampshire, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
2006 DNH 024, Counsel Stack Legal Research, https://law.counselstack.com/opinion/franz-v-purdue-pharma-co-nhd-2006.